Celgene Corp (CELG)
$98.67 0.07 (0.07%)
19:09 EDT CELG Stock Quote Delayed 15 Minutes
Previous Close $98.67
Market Cap 69.74B
PE Ratio 27.48
Volume (Avg. Vol.) 3.37M
Day's Range 98.18 - 98.85
52-Week Range 58.59 - 99.36
Dividend & Yield N/A (N/A)
CELG Stock Predictions, Articles, and Celgene Corp News
- From InvestorPlace
- From the Web
Biotech stocks overall are holding up fairly well amid recent market volatility. Look at which four biotech stocks to buy have staying power.
Amgen's purchase of Celgenes blockbuster psoriasis drug, Otezla is likely to strengthen its position in the immunology space and boost Amgen stock.
Trade talks gave a lift to stocks, while Johnson & Johnson will be in focus after the close. Here's what happened in the stock market today.
Celgene news for Thursday about it selling Otezla has CELG stock on the rise as it moves forward with the Bristol-Myers Squibb merger.
BMY stock may continue to bounce around, but the months-long selloff is now slowing because Bristol-Myers Squibb is still thriving.
Stock were hit on Thursday as investors try to parse through a deluge of earnings results. Here's what moved the stock market today.
Investors turned sour on BMY stock after the Celgene buyout. Will a solid Q2 earnings report change the sentiment for the better?
Trump says that Facebook and Alphabet should be sued, while Micron surged on earnings. Semiconductors got a big boost in the Nasdaq today as well.
AbbVie is buying Allergan, FedEx and Blackberry are reporting earnings and Microsoft is on the move. Here are our top stock trades.
The stock charts of EA, AAP and MGM have run through the technical trading wringer in front of today's action.
Celgene and Bristol-Myers Squibb stocks took a hit, video games rallied and Caesars Entertainment entered into a $17.3 billion merger. Here's the Nasdaq Today report.
Bristol-Meyers Squibb news for Monday has BMY stock taking a beating after announcing a delay to its merger deal with Celgene.
Zynerba landed a new patent for its Zygel product to use cannabidiol as a treatment for Autism Spectrum Disorder, sending ZYNE stock ripping.
The stock charts of CELG, AAL and MYL stock are going to start the new trading week out in a clear technical condition.
Bristol-Myers Squibb earnings for the first quarter of 2019 have BMY stock up Thursday on an earnings per share and revenue beat.
Investors are punishing Bristol-Myers on the markets more than they should. BMY stock's acquisition of Celgene isn't the only reason.
Celgene and Bristol-Myers got the green light from shareholders to move forward on the deal. More upside awaits for CELG stock.
Navellier RatingsPowered by Portfolio Grader
10 Stocks Set for Monster Growth
He found Apple at $4… Oracle at $6… Amazon at $40… Now legendary growth investor Louis Navellier is giving away his latest Research Report — for FREE!
Download your FREE COPY!